Congratulations to Dr. Doug Sborov for his leadership role in the GRIFFIN clinical trial that underwent a final analysis recently. The original study was published in Blood in 2020. The phase II GRIFFIN study showed important results with the investigational daratumumab quadruplet regimen in the treatment of newly diagnosed, transplant-eligible multiple myeloma. Of the patients in the study for a mean 49.6 months, a 55% reduction in the risk of disease progression or death was observed. “The study is an important step forward in improving the outcomes in these patients” said Dr. Sborov.